RBC Europe’s Atossa Therapeutics ATOS Stock Holding History

RBC Europe’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-21	Closed	-$1.04K	–	671
2021 Q3	$1.04K	Hold	21	–	–	﹤0.01%	1177
2021 Q2	$2.02K	Buy	+21	New	+$1.11K	﹤0.01%	1124

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RBC Europe's ATOS Position: Q4 2021 in Review

RBC Europe sold out of Atossa Therapeutics (ATOS) in Q4 2021, closing a stake of 21 shares — an estimated $1.04K sold.

RBC Europe first reported a position in ATOS in Q2 2021 and held it in 2 quarters. The position peaked at $2.02K in Q2 2021. 91 funds tracked by Wall St. Rank hold ATOS as of Q4 2021.

RBC Europe reported no remaining Atossa Therapeutics position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 21 Atossa Therapeutics shares in Q4 2021, an estimated $1.04K.
RBC Europe first reported a position in Atossa Therapeutics in Q2 2021 and held it in 2 quarters.
RBC Europe's Atossa Therapeutics position peaked at $2.02K in Q2 2021.
91 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.